Navigation Links
TGen and Scottsdale Healthcare begin study of new drug for patients with solid tumors

SCOTTSDALE, Ariz. June 17, 2014 The Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) are studying the safety and effectiveness of a new drug, AG-120, for treatment of patients with solid tumors, especially those with brain tumors and gallbladder bile duct cancer.

"AG-120 is designed specifically for those patients who carry the IDH1 gene mutation," said Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-In-Chief at TGen, and Chief Scientific Officer for the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and TGen that delivers new treatments to cancer patients based on precision medicine.

The IDH1 gene mutation is most commonly found in gliomas, which make up the largest group of "primary" brain tumors, those that start in the brain. Gliomas include all tumors arising from the gluey or supportive tissue of the brain. They represent about 30 percent of all brain tumors, and about 80 percent of all malignant brain tumors.

As with all brain cancers, gliomas are difficult to treat and many grow back after surgery, radiation and standard of care chemotherapy. Many drugs cannot get to the brain because of a filtering mechanism in the body called the blood-brain barrier.

"There is a great need for more effective treatments for patients with gliomas and other solid tumors, such as gallbladder bile duct cancer," said Dr. Von Hoff, who is the Principal Investigator for AG-120 clinical trial. This study will enroll as many as 50 patients. Researchers will use precision medicine to match treatments to patient's specific genomic, or molecular, makeups.

Mutations in isocitrate dehydrogenase (IDH) 1 and 2, originally discovered in 2008, occur in the vast majority of low-grade gliomas and secondary high-grade gliomas. IDH mutations are oncogenic, meaning they have the potential to cause cancer. These mutations occur early in the formation of gliomas and in gallbladder bile duct cancer.

AG-120 is produced by Agios Pharmaceuticals Inc., based in Cambridge, Mass.

IDH1 is a metabolic enzyme identified by Agios as a protein that is mutated in a wide range of malignant tumors. Agios and its collaborators recently demonstrated that IDH1 mutations initiate and drive cancer growth by blocking differentiation, or maturation, of primitive cells. According to Agios, the inhibition of these mutated proteins may lead to clinical benefit for those cancer patients whose tumors carry them.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related medicine news :

1. TGen and Scottsdale Healthcare cancer expert Dr. Von Hoff receives Hope Funds award
2. TGen and Scottsdale Healthcare cancer expert Dr. Daniel D. Von Hoff is honored by ASCO
3. Scottsdale Treatment Center Launches Program to Address Illicit Drug Use in Adults, Adolescents
4. Home Care Assistance of Scottsdale Launches New Website
5. Luxury Arizona Condos from The Statesman Group are Now Available for Purchase in Scottsdale/Phoenix, Arizona
6. Top Phoenix Hearing Aid Provider Opens New Office in Scottsdale, AZ
7. Younan Properties Announces Successful Financing of Scottsdale Shopping Center; Retail Promenade to be Renamed 7 Thousand Shea
8. Alice Branton Invites the Eyes of the World to Focus on Scottsdale, Arizona
9. Arizona Marijuana Doctor Helps Scottsdale Patients Achieve Green Wellness in the Copper State
10. Mahendra Kumar Trivedi to Host Retreat in Scottsdale, Arizona
11. TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of proteomic mapping
Post Your Comments:
(Date:12/1/2015)... Diego, CA (PRWEB) , ... December 01, 2015 ... ... and scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro ... mobile imaging results enhancements at the Radiological Society of North America (RSNA) 2015 ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., ... awarded a fixed price per sprint agile development contract to support the National ... over five years, provides software engineering, infrastructure, as well as operations and sustainment ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, ... addresses a main “pain point” for merging or aligning healthcare provider organizations—when mergers ... is signed. This quick-read guidance suggests that failing to recognize the power ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... With ... footage, and with full control over customization, the possibilities are truly endless, all with ... position randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, ...
(Date:12/1/2015)... ... December 01, 2015 , ... SonaCare Medical congratulates the University ... Innovation Award on November 18th. This prestigious award recognizes annually organizations that cultivate ... to the medical landscape. , The UCLH team won the award for their ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... pain, announced today that the company will present at the ... 1-3 at the Luxe Sunset Boulevard Hotel in ... of Relmada Therapeutics, will present on Thursday, December 3, at ... . Please register at least 10 minutes prior to ...
(Date:12/1/2015)... DIEGO , Dec. 1, 2015   MabVax ... drug development company, announces it has filed an Investigational ... Drug Administration (FDA) for the Company,s lead fully human ... to FDA acceptance, MabVax plans to initiate the Phase ... --> --> The planned Phase ...
(Date:12/1/2015)... 1, 2015   Craneware, Inc ., the ... today announced the company will showcase a new ... ® solution at the American Society for ... . The new features are focused on simplifying ... and managing enterprise-wide pharmacy charges to ensure compliance ...
Breaking Medicine Technology: